Skip to main content
. 2021 Dec 30;126(8):1168–1177. doi: 10.1038/s41416-021-01684-4

Fig. 3. CB213 NHP pharmacokinetics and anti-drug antibodies.

Fig. 3

a CB213 PK and ADA in two female cynomolgus macaques: animals 102 and 103. b Cartoon of CB213 structure. A Schematic of CB213 is shown. Individual VH are shown as globular domains, with stylised glycine/serine linkers intervening in dark grey. The diagram is not to scale. c Schematic of the MSD-based CB213 PK bridging assay. Molecules that can simultaneously bind to LAG3 and to PD1 are detected. d Schematic of the MSD-based ADA assay. Molecules that can bind to CB213 when bound to LAG3 that contain an IgG light chain are detected.